Belite Bio Inc ADR BLTE

$169.82 +3.16 (1.90%)

Valuation

Market cap
6,682,331,000
Revenue TTM
$0
Net income TTM
$-77,610,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
141,900
Avg volume
186,218
Day's range
$167.18 – $172.74
Shares out
40,272,000
Stochastic %K
16%
Beta
-1.23
Analysts
Strong Sell
Price target
$228.89

Price

Company profile

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geog...

Show more

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an retinol binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.

Industry
Biotechnology
Sector
Healthcare
Phone
858 246 6240
Website
https://www.belitebio.com
Address
12750 High Bluff Drive, Suite 475, San Diego, United States

Latest news

Stocktwits

SmoldyShatStone Sep 24, 12:50 PM
$OCGN lol just look at the competitor to Ocugen. $BLTE has a superb management with only 40M shares and a stock price of $160. They didn’t constantly need to dilute their investors and give themselves millions of bonuses each year and have stellar data with filing in half the time Ocushit took to do anything. You can have the best science in the world, but if your management team is trash, the company will ultimately fail. That’s why they hire these garbage pumpers to get others to believe $100 plus 😂😂
0 replies
Merlintrader Sep 23, 7:00 PM
Belite Bio ($BLTE): Tinlarebant Filed in Japan Under Sakigake, FDA PDUFA February 12, 2027 Free Biotech Catalyst Calendar on Merlintrader. https://www.merlintrader.com/belite-bio-blte-stock-hub/
0 replies
SmoldyShatStone Sep 12, 3:03 AM
$OCGN market also looks into the CEO and management team too little Simbha 😂😂 when a CEO is known for constantly moving goalposts, diluting the living Shanksters out of the investors and lots of evidence of wrongdoing, they might not want to invest. Take a look at $BLTE 40M share total and beautiful execution by the management team on how to get to filing without diluting the ell out of investors and giving themselves millions in bonuses and salary increases
0 replies
Flintstone_1 Sep 11, 4:50 AM
$OCGN Could we compare this with $BLTE if we succeed finally ???
0 replies
SmoldyShatStone Sep 8, 9:54 PM
$OCGN Belite Bio $BLTE is the perfect example of a company with stellar management who don’t issue dilution votes every few months. Their management planned a beautiful execution and managed their funds well while Shanky is constantly asking for millions in bonuses and salary boosts. Hiring garbage business advisory board scrubs, failed executive team with zero sense of urgency or managing timelines. I’ll say it again… once this shit ass CEO Shankster is ousted, that’s when you will see real growth here. Enjoy the 250M share dilution baggies 😂 Shanky is truly working diligently for you all and hasn’t been able to sleep for months 😂😂
0 replies
Quantumup Sep 8, 6:03 PM
Jefferies⬆️ $TARS' PT to $105 from $88 and reiterated Buy. $ABBV NVS - ALC $BLTE ALC NBY Jefferies said in its note -- TARS stock has rallied post Q2 EPS on a combo of (1) increased Xdemvy 2026 guidance and recent scripts suggest a strong Q3; (2) Alkeus tuck-in for a Phase III-ready rare-disease asset injects new biotech pipeline into the narrative (we est $1B peak); and (3) iRenix deal for another Phase III asset. Valuation at $4B cap remains inexpensive over the long term, given multiple pipeline data-card flips over the next 1-3 years + strong Xdemvy base biz. PT to $105.
0 replies
Spicy_Trade Sep 6, 8:33 PM
Belite Bio, Inc ( $BLTE ) SpicyTrade - Daily Stock Analysis https://youtu.be/wHGRs7xcOSE?si=UZsHDtzfZ4DJcFyc
0 replies
fallondpicks Sep 5, 9:42 PM
13 #stockbreakouts $BLTE, $EPRX, $NX (gap and base), $TITN. One sub-$1, Two $1-2.
0 replies